Loading news...
Private credit executive to lead newly launched debt private placements group, expanding financing solutions for investment banking clients. NEW YORK, March 17, 2026 /PRNewswire/ -- Oppenheimer & Co. Inc. – a leading investment bank, wealth manager and a subsidiary of Oppenheimer Holdings Inc. (NYSE: OPY) – today announced that Eric Nortman has joined the firm as Managing Director, Head of Debt Private Placements.
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that the company will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference. Fred Burke, President and Chief Executive Officer, and David Morris, Chief Financial Officer, will participate in a fireside chat on Monday, March 16, 2026, at 10:40 a.m. Eastern Time. A live audio webcast of the session will be available at https://investors.guardianpharmacy.com. A replay will be a.
HINGHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will be participating at the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, held March 16-19, 2026.
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present at the upcoming virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference. Pulse Biosciences' Management is scheduled to present on Wednesday, March 18, 2026, at 10:40 am ET. A live and recorded webcast of the fireside chat will be availabl.
Jade Biosciences, Inc. (JBIO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Prepared Remarks Transcript
LPL Financial (NASDAQ: LPLA - Get Free Report) and Oppenheimer (NYSE: OPY - Get Free Report) are both finance companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation. Volatility and Risk LPL Financial has a beta of
Seasoned municipal finance leader joins the firm's Public Finance Investment Banking Group and will be based in Los Angeles NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Oppenheimer & Co. Inc. (Oppenheimer), a leading investment bank, wealth manager and a subsidiary of Oppenheimer Holdings Inc. (NYSE: OPY), today announced it has hired Vien Le as Managing Director in the firm's Public Finance Investment Banking Group. Le will be based in Oppenheimer's Los Angeles office and will report to Beth Coolidge, Managing Director and Head of Public Finance.
CHICAGO and FORT WORTH, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Dan Schmitt, President & CEO of the Company, will present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 at 9:20 a.m. ET.
BOCA RATON, Fla.--(BUSINESS WIRE)--Cross Country Healthcare, Inc. (the “Company”) (Nasdaq: CCRN) announced today that it is scheduled to participate in two upcoming conferences: The Truist Securities Virtual Human Capital Conference taking place March 12-13, 2026, with one-on-one investor meetings on Thursday, March 12. The Oppenheimer 36th Annual Healthcare MedTech & Services Conference taking place March 16-19, 2026, with one-on-one investor meetings on Tuesday, March 17. In attendance an.
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at Oppenheimer 36th Annual Healthcare Life Sciences Conference which is being held virtually. The presentation will be on Thursday, February 26, 2026 at 2:40pm ET.
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held in a virtual format February 25-26, 2026.
CrowdStrike continues to be the leader in the next-generation endpoint security space. SentinelOne appears to have had the biggest positive change in sentiment among channel partners.
Oppenheimer Holdings, Inc. (NYSE: OPY - Get Free Report)'s stock price passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $73.84 and traded as high as $90.40. Oppenheimer shares last traded at $88.61, with a volume of 43,010 shares traded. Analysts Set New Price Targets Several
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26th, 2026 at 2:40 p.m. ET.
Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 3:20 p.m. ET. A live webcast will be available on Kiora's investor relations website, ir.kiorapharma.com, on the IR homepage and under the News & Events section.
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25-26, 2026.
BETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company's management team will participate in a fireside chat and one-on-one meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held Wednesday, February 25th through Thursday, February 26th.
MORRISTOWN, N.J., Feb. 18, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 8:40 AM EST.
HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format on February 25-26, 2026. Presentation Details: Event: Oppenheimer 36 th Annual Healthcare Life Sciences Conference Date: Wednesday, February 25, 2026 Time: 8:00 – 8:30 a.m.